TLIS
Market cap | $3.24 Million |
---|---|
Enterprise Value | $-37,822,379.00 |
Dividend Yield | $0 (0%) |
Earnings per Share | $-34.12 |
Beta | 1.57 |
Outstanding Shares | 1,822,422 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.06 |
---|---|
PEG | 0.15 |
Price to Sales | - |
Price to Book Ratio | 0.06 |
Enterprise Value to Revenue | -126.07 |
Enterprise Value to EBIT | 0.77 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | -0.5 |
Debt to Equity | 0.39 |
No data
No data
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginnin...